Biomarkers in prostate cancer: what's new?

DA Sartori, DW Chan - Current opinion in oncology, 2014 - journals.lww.com
DA Sartori, DW Chan
Current opinion in oncology, 2014journals.lww.com
Several new tests, as discussed in this review, have become available during the last 2
years. Although the intended use of most of these tests is to distinguish PCa from benign
prostatic conditions with better sensitivity and specificity than prostate-specific antigen,
studies have shown that some of them may also be useful in the differentiation of aggressive
from nonaggressive forms of PCa.
Summary
Several new tests, as discussed in this review, have become available during the last 2 years. Although the intended use of most of these tests is to distinguish PCa from benign prostatic conditions with better sensitivity and specificity than prostate-specific antigen, studies have shown that some of them may also be useful in the differentiation of aggressive from nonaggressive forms of PCa.
Lippincott Williams & Wilkins